Navigation Links
WX Crowned 'Chemistry CRO of the Year' by Pfizer

SHANGHAI, China, April 4, 2008 /Xinhua-PRNewswire-FirstCall/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it was awarded the 2007 Chemistry CRO of the Year Award by the Pfizer Chemistry Sourcing Center of Emphasis (CoE).

(Logo: )

Dr. Richard Connell, Head of the Chemistry Sourcing CoE, presented the award plaque to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, at a recent Steering Committee meeting held in Groton, Connecticut. WuXi PharmaTech has enjoyed a close and cooperative relationship with Pfizer for many years, with collaborations ranging from synthetic chemistry, parallel medicinal chemistry (PMC), and ADME to bioanalytical services. The award recognizes in particular the outstanding collaboration of the WuXi and Pfizer teams in an effort to shorten the cycle times between requests for and delivery of parallel medicinal chemistry.

Pfizer's Centers of Emphasis state their mission as "Delivering Value Through Partnership." The success of their partnership with WuXi was certainly reflected in this year's presentation of their Top Chemistry CRO Award.

As the largest pharmaceutical, biotechnology and medical device contract research organization, WuXi collaborates with Pfizer in a number of drug discovery and development areas. Dr. Gonghua Pan of Pfizer, a key member of the collaboration, commented on the impact, "With WuXi's help, we reduced the average time from submitting the request to shipping of the finished product from 65 days in 2006 to 43 days in 2007, and at no increase in cost. This improvement reflects their own corporate commitment to continuous improvement - a commitment embedded in their slogan, 'we are determined to serve you better(R).'"

"We are very honored to receive this recognition from Pfizer, one of our largest customers for many years, and we really appreciate the trust and support Pfizer has given us. In order to better serve our customers we are building a global service and resource platform that has both small molecule and biologics capabilities covering early stage discovery to commercial manufacturing. By continuously improving our services and operation excellence, we will live up to our service creed 'We are determined to serve you better(R),'" commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

About WuXi PharmaTech

WuXi PharmaTech, headquartered in Shanghai, China, is a leading global pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the U.S. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to pharmaceutical, biotechnology and medical device companies. Our services are designed to assist our global customers in shortening the time and lowering the cost of drug and medical device R&D by providing cost-effective and efficient outsourcing solutions. For more information, please visit:


Sherry Shao

WuXi PharmaTech Inc.

+86 (21) 5046-4002

SOURCE WuXi PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital(TM) Initiative
2. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
3. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
4. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
5. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
6. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
7. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
8. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
9. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
10. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
11. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation ... on being named to Deloitte's 2015 Technology Fast 500 list of the fastest ... AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic tooth movement ...
Breaking Biology Technology:
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... Minn. , Oct. 29, 2015   MedNet ... supports the entire spectrum of clinical research, is pleased ... Minnesota High Tech Association (MHTA) as one of only ... in the "Software – Small and Growing" category. The Tekne ... individuals who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):